Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
CStone Pharmaceuticals
Astellas Pharma Inc
Mirati Therapeutics Inc.
Akeso
Merck Sharp & Dohme LLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
EMD Serono
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NuCana plc
Providence Health & Services
UCB Pharma
Shanghai Junshi Bioscience Co., Ltd.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Amphia Hospital
AstraZeneca
Tianjin Medical University Cancer Institute and Hospital
Hoffmann-La Roche
National Cancer Centre, Singapore
Shanghai JMT-Bio Inc.
Lumos Pharma
Eli Lilly and Company
ASLAN Pharmaceuticals
SuZhou Stainwei Biotech Inc.
UNC Lineberger Comprehensive Cancer Center
Ziekenhuis Oost-Limburg
SCRI Development Innovations, LLC
PharmaEngine
NYU Langone Health
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Pittsburgh
University of Pittsburgh
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute
Northwestern University
Mayo Clinic
AstraZeneca